Angiogenesis Therapy for the Treatment of Erectile Dysfunction

Journal of Sexual Medicine

Volumn 7, Issue 7, 2010, Pages 2554-2563

  Lysiak, Jeffrey J ^a   Kavoussi, Parviz K ^a   Ellati, Riyad T ^a   Steers, William D ^a   Annex, Brian H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenovirus; Angiogenesis; Erectile Dysfunction; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; EPHRIN; GROWTH DIFFERENTIATION FACTOR 5; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ERECTILE DYSFUNCTION; GENE DELIVERY SYSTEM; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SEXUAL FUNCTION; STEM CELL TRANSPLANTATION;

EID: 77955155084     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01830.x     Document Type: Article

References (84)

1. Haczynski J, Lew-Starowicz Z, Darewicz B, Krajka K, Piotrowicz R, Ciesielska B. The prevalence of erectile dysfunction in men visiting outpatient clinics. Int J Impot Res 2006, 18:359-63.
2. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989, 320:1025-30.
3. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326:90-4.
4. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338:1397-404.
5. Morelli A, Vignozzi L, Filippi S, Mancina R, Maggi M. Erectile dysfunction: Molecular biology, pathophysiology and pharmacological treatment. Minerva Urol Nefrol 2005, 57:85-90.
6. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006, 67:1043-8.
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-6.
8. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994, 330:1431-8.
9. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27-36.
10. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992, 90:1168-72.
11. Azadzoi KM. Vasculogenic erectile dysfunction: Beyond the haemodynamic changes. BJU Int 2006, 97:11-6.
12. Burnett A. Significance of the nitric oxide cascade in erectile function. Drugs Today (Barc) 2000, 36:155-62.
13. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995, 52:485-9.
14. Burnett AL. Erectile dysfunction. J Urol 2006, 175:S25-31.
15. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005, 32:v-95.
16. Lue TF. Erectile dysfunction. N Engl J Med 2000, 342:1802-13.
17. Kendirci M, Trost L, Sikka SC, Hellstrom WJ. The effect of vascular risk factors on penile vascular status in men with erectile dysfunction. J Urol 2007, 178:2516-20. discussion 2520
18. Davies KP, Tar M, Rougeot C, Melman A. Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int 2007, 99:431-5.
19. Burnett AL. General use of animal models for investigation of the physiology of erection. Int J Impot Res 2001, 13:135-9.
20. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999, 99:1726-32.
21. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001, 7:425-9.
22. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003, 3:643-51.
23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
24. Burchardt T, Burchardt M, Chen MW, Buttyan R, de la Taille A, Shabsigh A, Shabsigh R. Expression of VEGF splice variants 144/145 and 205/206 in adult male tissues. IUBMB Life 1999, 48:405-8.
25. Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH, Hagen PO, Donatucci CF. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 2001, 165:1310-5.
26. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-43.
27. Ware JA. Too many vessels? Not enough? The wrong kind? The VEGF debate continues. Nat Med 2001, 7:403-4.
28. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-76.
29. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-34.
30. Wu HM, Huang Q, Yuan Y, Granger HJ. VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 1996, 271:H2735-9.
31. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998, 274:H1054-8.
32. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994, 93:662-70.
33. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15:1751.
34. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996, 93:2576-81.
35. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60:203-12.
36. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest 1997, 76:245-55.
37. Liu X, Lin CS, Graziottin T, Resplande J, Lue TF. Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells. J Urol 2001, 166:354-60.
38. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: Differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007, 101:948-56.
39. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007, 13:5544s-8s.
40. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001, 276:26969-79.
41. Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007, 7:1379-93.
42. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000, 275:9102-5.
43. Kontos CD, Cha EH, York JD, Peters KG. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 2002, 22:1704-13.
44. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999, 274:8347-50.
45. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001, 114:1439-45.
46. Sulis ML, Parsons R. PTEN: From pathology to biology. Trends Cell Biol 2003, 13:478-83.
47. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu Rev Biochem 2001, 70:247-79.
48. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 2001, 98:4622-7.
49. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 2003, 53:109-17.
50. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997, 90:3322-31.
51. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P, Lin C, Fiebiger E, Wei X, Wu Y, Hicklin D, Bohlen P, Detmar M. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004, 104:1048-57.
52. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998, 17:303-11.
53. Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S, Yabana N, Alitalo K, Shibuya M. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 2006, 26:2019-26.
54. Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001, 165:419-23.
55. Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M, Piao S, Han JY, Kim IH, Koh GY, Suh JK. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 2006, 13:705-15.
56. Rampino T, Gregorini M, Dal Canton A. Scatter Factors in renal disease: Dr. Jeckyll and Mr. Hyde? Cytokine Growth Factor Rev 2009, 20:77-85.
57. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-84.
58. Gentile V, Modesti A, La Pera G, Vasaturo F, Modica A, Prigiotti G, Di Silverio F, Scarpa S. Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction. J Androl 1996, 17:96-103.
59. Aversa A, Basciani S, Visca P, Arizzi M, Gnessi L, Frajese G, Fabbri A. Platelet-derived growth factor (PDGF) and PDGF receptors in rat corpus cavernosum: Changes in expression after transient in vivo hypoxia. J Endocrinol 2001, 170:395-402.
60. Miao H, Wang B. Eph/ephrin signaling in epithelial development and homeostasis. Int J Biochem Cell Biol 2009, 41:762-70.
61. Dravis C, Yokoyama N, Chumley MJ, Cowan CA, Silvany RE, Shay J, Baker LA, Henkemeyer M. Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development. Dev Biol 2004, 271:272-90.
62. Lee M, Ryu JK, Piao S, Choi MJ, Kim HA, Zhang LW, Shin HY, Jung HI, Kim IH, Kim SW, Suh JK. Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. J Sex Med 2008, 5:1355-64.
63. Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU, Kim SW, Suh JK. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res 2005, 17:326-34.
64. Dall'Era JE, Meacham RB, Mills JN, Koul S, Carlsen SN, Myers JB, Koul HK. Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model. Int J Impot Res 2008, 20:307-14.
65. Lin G, Banie L, Ning H, Bella AJ, Lin CS, Lue TF. Potential of adipose-derived stem cells for treatment of erectile dysfunction. J Sex Med 2009, 6(3):320-7. suppl
66. Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen PO, Donatucci CF. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: A preliminary study. Int J Impot Res 2000, 12:334-9.
67. Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF. Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med 2006, 3:223-32.
68. Shirai M, Yamanaka M, Shiina H, Igawa M, Kawakami T, Ishii N, Lue TF, Fujime M, Dahiya R. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun 2006, 341:755-62.
69. Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int 2002, 89:955-60.
70. Lee MC, El-Sakka AI, Graziottin TM, Ho HC, Lin CS, Lue TF. The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol 2002, 167:761-7.
71. Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, de la Taille A, Shabsigh A, Frank J, Shabsigh R. Application of angiogenic factors for therapy of erectile dysfunction: Protein and DNA transfer of VEGF 165 into the rat penis. Urology 2005, 66:665-70.
72. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol 2007, 22:458-63.
73. Dai Q, Silverstein AD, Davies MG, Hagen PO, Donatucci CF, Annex BH. Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hypercholesterolemic rabbits. J Urol 2003, 170:664-8.
74. Fandel TM, Bella AJ, Lin G, Tantiwongse K, Lin CS, Pohl J, Lue TF. Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2008, 5:1866-75.
75. Ning H, Liu G, Lin G, Yang R, Lue TF, Lin CS. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. J Sex Med 2009, 6:967-79.
76. Schouten BW, Bohnen AM, Bosch JL, Bernsen RM, Deckers JW, Dohle GR, Thomas S. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: Results from the Krimpen Study. Int J Impot Res 2008, 20:92-9.
77. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: Common links. Eur Urol 2007, 52:1590-600.
78. La Vignera S, Calogero AE, Cannizzaro MA, Vicari E. Erectile vascular dysfunction and analysis of the risk factors related to it: Clinical experience. Minerva Endocrinol 2007, 32:17-21.
79. Kaya C, Ergelen M, Ilktac A, Karaman MI. Impaired elasticity of aorta in patients with erectile dysfunction. Urology 2007, 70:558-62.
80. Kapur V, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. Part I: Pathophysiology and mechanisms. Rev Cardiovasc Med 2007, 8:214-9.
81. Elesber AA, Solomon H, Lennon RJ, Mathew V, Prasad A, Pumper G, Nelson RE, McConnell JP, Lerman LO, Lerman A. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006, 27:824-31.
82. Schwarz ER, Rodriguez J. Sex and the heart. Int J Impot Res 2005, 17(1):S4-6. suppl
83. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005, 59:225-9.
84. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004, 16:350-3.